These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7917768)

  • 1. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    Minton NA
    Br J Clin Pharmacol; 1994 Jun; 37(6):525-30. PubMed ID: 7917768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3 antagonists in the pigeon.
    Wolff MC; Leander JD
    Pharmacol Biochem Behav; 1995 Nov; 52(3):571-5. PubMed ID: 8545476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
    Minton N; Swift R; Lawlor C; Mant T; Henry J
    Clin Pharmacol Ther; 1993 Jul; 54(1):53-7. PubMed ID: 8101150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and preclinical antiemetic properties of ondansetron.
    Tyers MB
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).
    Darmani NA; Chebolu S; Amos B; Alkam T
    Pharmacol Biochem Behav; 2011 Oct; 99(4):573-9. PubMed ID: 21683089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
    Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
    Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.